Give simply more
1
2
What is PraxisPlatform?
PraxisPlatform is an ICT-supported* patient
communication platform which is focused on:
• sending therapy-related information to patients to
increase their adherence/compliance in medicinal
therapy and medical device use
• enabling pharmacy care services to large patient
populations
We have successfully commercialized a streamlined platform
which brings more health to patients, more revenue to pharma
and medical device companies and savings to payers.
* ICT – Information and communication technology
3
About the company
• PraxisPlatform has been developed by health economists and
managed care experts in Central Europe, a challenging
environment characterized by limited health care resources and
low health consciousness of the population.
• We employ a staff of about 30 people in Budapest, specialized
in the following areas:
• Clinical content development
• Sales & Marketing
• Customer service (incl. call center)
• IT development
3
4
PraxisPlatform has been through four years of quick
expansion
In December 2012,
In Summer 2013, the
After some years at
the Hungarian sick
fund, a small team
of committed
professionals starts
to develop
PraxisPlatform in
June 2010
In May 2011,
PraxisPlatform and
Magyar Telekom
sign a commercial
deal and Magyar
Telekom markets the
product in Hungary
Since then projects
are launched every
month in patient
adherence
management.
PraxisPlatform teams up
with one of the leading
Hungarian pharmacy
chains to offer pharmacy
care services and to
manage its client loyalty
programme
100.000th patient is
registered
In 2013, PraxisPlatform
launches a disease
registry module and
offers a transplantation
registry
In December 2010, the
first pilot project in
patient adherence
management starts in
co-operation with the
Hungarian subsidiary of
Deutsche Telekom
group and SanofiAventis
By early 2012,
PraxisPlatform is
able to offer
complex market
research services
and launches its
real-life evidence
generation
module (noninterventional
studies)
4
5
PraxisPlatform in figures (1 Feb 2014)
25
4.700
60% of all
potential partners
30% of all active physicians,
1.500 active users*
Companies
Went live
Physicians
1 Oct 2010
112
Pharmacies **
Geographies
Hungary
112.000
Patients
50
5
Programmes
Modules***
* Inactive physicians who have contracted with PraxisPlatform, can be reached by PraxisPlatform, but have not enrolled any
patients to programmes yet. They are still learning system functions or waiting for the appropriate programme for their patients.
** In co-operation with one of the largest Hungarian pharmacy chains
*** Patient education and pharmacy care, market research, clinical trial, patient registry, screening
5
6
What services are currently offered by PraxisPlatform?
Patient
education
and
pharmacy
care
Disease
registries
Real-life
evidence
generation
(NIS, PAES,
MES/PAS)*
Primary
market
research
Patient
screening
Data mining
Pharmacovigilance
E-detailing
Core module
Independent module
Additional services
* NIS: Phase IV non-interventional trials, PAES: Post-authorization efficacy studies , MES/PAS:
Managed entry schemes / patient access schemes
7
Current situation of PraxisPlatform
 PraxisPlatform has reached a dominant position in
Hungary, a Central European EU member state of 10
million people where further growth opportunities are
limited because of the size of the country
 The value of Hungary is that it is often used as a test
market by Big Pharma: if an idea works in Hungary, it
is likely to work in several other markets
1
PraxisPlatform is
interested in
TECHNOLOGY TRANSFER
to major geographies with
developed health care
markets
 PraxisPlatform has an infrastructure to service more
patients, physicians and doctors in more geographies
 PraxisPlatform has the clinical, ICT and sales knowhow which can be transferred to absolutely different
regions
 PraxisPlatform is an integrated platform which is
difficult to copy: individually existing separate modules
do not pose a threat to the business concept
 PraxisPlatform has IRP protection for the EU
2
PraxisPlatform is
interested in
COMMERCIALIZATION
AGREEMENTS to extend its
services to other regions
7
8
PraxisPlatform – Technology transfer and
commercialization deal opportunity




Technology transfer
Vermarktung
Commercialization
(„clone”)
(„service”)
PraxisPlatform has been developed
with approx. 50.000 IT developer
hours over 3 years
Based on our experience and
knowhow, our team is able to develop
and test a clone of our system in 3-4
months
In this model, our team builds, test
and launches the clone and trains the
buyer
We are not involved in further
operations and all rights stay with the
buyer for the relevant geography
(„Dienstleistung”)



In this model, we commit ourselves to
operating PraxisPlatform with a
business partner who wishes to
introduce this service in a new
geography
We co-develop the business model, we
carry out the necessary modifications
and we maintain active involvement in
operations via our service center in
Budapest
All rights stay with us, and we set up a
revenue or profit sharing scheme with
the commercial partner
ABOUT
THE
PROGRAMMES
EDUCATIONAL
10
Starting point: Non-adherence, the most devastating
illness of the modern world
100%
Patients’ adherence to treatment is disconcertingly low
throughout the developed world in practically all major
chronic diseases.
100%
% of patients of therapy
90%
80%
Large scale study (n=459.034), Hungary, statins
70%
60%
50%
40%
46%
38%
30%
29%
20%
25%
22%
19%
10%
18%
0%
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Months after therapy initiation
Source: Dankó – Frang – Molnár: Patients’ adherence to statin treatment. Corvinus University of Budapest, 2010, n=
459.034, based on National Health Insurance Fund financial database, 2007.01.01 – 2009.12.31
10
19
11
The key goal of PraxisPlatform is to help, educate and
empower
Product
Termék
Communication
tool and content
Kommunikáci
ós eszköz és tartalom
Other
Services
Egyéb
szolgáltatások
Motivated, health-conscious and
satisfied patient, who is healthier
11
12
How educational programmes work…
HEALTH CARE
COMPANIES
They commission PraxisPlatform to
(co-)develop therapy management,
adherence management and pharmacy care
programmes for their products and services.
PHYSICIANS
PraxisPlatform usually works together with
pharma and medical device companies but
health insurers, patient advocacy groups
and clinical organizations are also valued
clients.
PHARMACISTS
They enrol patients
(customers) into the
programmes offered by
PraxisPlatform.
They receive feedback
about their patients’
health behaviour. They
are remunerated
proportionally to their
workload in a legal and
ethical way.
They enrol patients
(customers) into the
programmes offered by
PraxisPlatform.
They receive feedback
about their patients’
health behaviour. They
are remunerated
proportionally to their
workload in a legal and
ethical way.
PATIENTS
Patients receive therapy-related information, general health information, pharmacy care information and eventually
nursing and along an optimized timeline. Patients receive all services without payment.
Patients can contact their physician and pharmacist via PraxisPlatform. Patients form patient communities.
12
13
Case study 1: supporting the launch of an original drug
• Combination product for the treatment of benign prostatic
hypertrophy
• Active substance: dutasteride+tamsulosine
• Programme duration for each patient: 6 months
• Segmentation fee: 6.5 euro
• Target group: urologists (approx. 300 registered specialists)
• Goal: support to field activity upon product launch
13
14
Brief summary of the results
Persistence improvement is between 15 and 20 percent. Active group: patients who have
received full education. Control group: patients who have not received full education.
14
15
Case study 2: Replacing sales activities for an offpatented original drug
• The programme was launched for patients who received lipidlowering therapy because of their pathodologically high
trigliceride level and unfavourable cholesterol level.
• Active substance: fenofibrate
• Programme duration: 6 months
• Segmentation fee: 3.5 euro
• Number of enrolled patients: 5045
• Medical target group is too wide to be covered by field force:
more than 2000 doctors, incl. internal medicine specialists, GP’s
and cardiologists
• Goal: subsitution of field force activity while maintaining the
market position of the product
15
16
Brief summary of the results
We have data about patient persistence in fibrate lipid-lowering
therapy in Hungary. The analysis is based on the data of the
Hungarian National health Insurance Fund Administration..
Source: Molnár M. P. – Pálosi M. (2012): Patient adherence
(persistence) in fibrate lipid-lowering therapy, Medical Tribune,
October 2012
The persistence curve for the active group is based on a random
phone survey in which a representative sample of 100 enrolled
patients (based on age, gender and residence) was interviewed
about their medication-taking habits.
Persistence increased more than twofold. 75 per cent of patients were on newly initiated
therapy. As a result, sales stabilised and showed an increase of 2 per cent despite the
cancellation of all field force activities.
16
17
Case study 3: replacing sales acitivies for an offpatented original drug
• The programme was designed for patients who suffer from
osteoporosis. It helps them possess a deeper knowledge of the
disease and follow medicinal therapy more properly.
• Active subtance: alendronic acid
• Programme duration for patients: 7.5 months
• Segmentation fee: 6.5 euro
• Medical target group: wide scope of physicians (GP’s, orthopedic
surgeons, traumatologists, rheumatologists
• Goal: substitution of field force activity, protection of market
positions
17
18
Brief summary of the results
We have data about patient persistence in oral bisphosphonate
therapy in Hungary. The analysis is based on the data of the
Hungarian National health Insurance Fund Administration..
The persistence curve for the active group is based on a random
phone survey in which a representative sample of 100 enrolled
patients (based on age, gender and residence) was interviewed
about their medication-taking habits.
Persistence increased almost twofold. 78 per cent of patients were on newly initiated therapy. As
a result, the downward trend of sales was halted and stabilized.
19
Case study 4: supporting an oncological original drug
• The programme was designed for patients suffering from HER2+
metastatic breast cancer.
• Active substance: Lapatinib
• Porgramme duration for patients: 6 months
• Segmentation fee: none
• Goal: To enable physicians to help their breast cancer patients
better cope with their condition and follow medicinal therapy
more properly, with special regard to eventual side effects
• Medical target group: clinical oncologists
• The programme offered comprehensive medical care including
personal visits at the patient’s home.
19
20
Brief summary of the results
Although the programme was not expected to prolong therapy duration with end-stage patients,
such improvement was in fact registered. This is attributable to the appropriate management of
side effect during therapy.
21
Programmes and therapeutic areas
Range of therapeutic areas covered by PraxisPlatform:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Hypertension
Incontinence (diaper)
Asthma
Prostate hypertrophy
Anticoagulant therapy
Parinson’s
COPD
Breast cancer
Arthrosis
Depression
Hyperlipidaemia
HPV treatment
Heart failure/angina pectoris
Stroke
Diabetes mellitus (measurement)
•
•
•
•
•
•
•
•
•
•
•
•
•
Osteoporosis
Gastrooesophagialis reflux
Chronic myeloid leukaemia
Allergy
Erectile dysfunction
Cachexia-anorexia – oncology
Diabetes mellitus
Cardiovascular disease
Metabolic syndrome
Health promotion/prevention
Pregnancy
Probiotics
Inflammatory Bowel Disease
21
22
Parts of educational programmes
Basic programme data
Deadlines, goals and therapy, sponsoring health care company, financing,
description, programme messages
Information leaflet for physicians
about therapy & drug, how to enrol patients in a programme
Information leaflet for patients
about therapy & drug; suggestions for the therapy
Programme messages
Patients can read (or listen to) all programme messages (email, text, recorded
voice message) already sent by PraxisPlatform. For physicians all programme
messages are available.
Quiz
The quiz is dedicated to patients in a specific programme and consists of questions about the therapy, providing a possibility for the patient to
test his or her knowledge about the therapy.
Questionnaire
At the end of a programme, patients can fill in a satisfaction survey serving for the evaluation of the programme.
Diary
Patients in a programme can fill in a daily or weekly ‚diary’ consisting of questions about the specific therapy and/or the patient’s medical
condition. The patient’s physician can read the diary entries.
Statistics
Statistics about the patients in the programme
Patient calls
In certain programmes, the involved physician has to carry out consultations with the patient via phone call.
22
ABOUT
MARKET RESEARCH
24
Market research
Physicians can be enrolled into programme-specific or programme-independent market
research. They are compensated for filling in the market research questionnaire.
24
ABOUT
CLINICAL TRIALS
26
Clinical trials
Within PraxisPlatform’s real-life evidence generation module, physicians can be invited to
program-specific or program-independent, prospective, non-interventional clinical studies. The
PraxisPlatform system is able to manage the whole process of a clinical trial from enrolling a
patient into the trial through filling out the visit data up to handling the financial processes
(both physicians and supporting health care company).
26
ABOUT DISEASE REGISTRIES
28
Disease registry
PraxisPlatform offers to specific therapeutic areas disease registries with the following main
functions:
•
invited physicians can enrol their patients into a
registry
•
in the registry
questionnaires
•
physicians are notified about recommended patient
visits via email
•
patients can also be notified about recommended
visits via email, text message or voice message
•
the module can handle the financial processes related
to the physician's activity
module,
they
can
fill
in
visit
28
29
Transplant registry
The transplant registry is a specific patient registry enabling physicians working at a transplant
institute
1. to enrol their patients as recipients in the transplant registry
2. to enter transplant-specific donor data into the donor database
3. to fill in all relevant medical data of transplant operations.
29
BENEFITS OFFERED BY
PRAXISPLATFORM TO ITS
CLIENTS
31
How do patients benefit from PraxisPlatformTM?
• Free access to all patient features of PraxisPlatformTM
• Guidance to take medicines and use medical devices properly
• Guidance on lifestyle, health behavior and adherence to therapy
• Easy-to-access web content about disease and treatment
• Additional, flexible contact with treating specialist
• Comprehensive call center support (active and passive)
• Web-based patient communities
• In certain programmes: totally interactive features
• Patient retention is 98% in our running programmes
31
32
What are physicians’ and pharmacists’ benefits?
• Free access to all core modules
• Easy and tailor-made communication with patients, saving time and
reducing workload
• Possibility to access large populations at no cost*
• Access to a comprehensive range of ready-to-send programmes
uploaded by pharmaceutical and medical device companies
• Telemedicine and virtual chronic care features
• Possibility to participate in clinical research and market surveys
• Remuneration proportional to time spent on data management
• Feedback on patients’ adherence and drug consumption
32
33
Benefits offered by PraxisPlatform to health care
companies
Clinical benefits
• Stronger adherence to treatment, better
utilization of proprietary health technologies
• Higher real-life therapeutic effectiveness
• Lower risk of switches and therapy
discontinuation
• Possibility to participate in patient
education
Commercial benefits
• Increasing revenues
• Higher adherence / persistence
• Higher brand awareness
• Higher perceived drug value
• Balanced marketing channel mix
• Favorable programme cost structure
• Low costs of reaching patients
• Targeted, flexible campaigns
33
MAJOR REFERENCES
PRAXISPLATFORM
OF
35
Major references of PraxisPlatform
35
CONTACT:
info@praxisplatform.hu